NYU Langone Health performs the world’s first whole-eye and partial-face transplant for military veteran

A surgical team from NYU Langone Health performed the world’s first whole-eye and partial-face transplant for a 46-year-old military veteran from Arkansas who survived a work-related high-voltage electrical accident.

GLP-1 drug exenatide shows no benefit for Parkinson’s in new study

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, finds a new study led by

February 5, 2025

Hoth and Aronnax partner for HT-KIT cancer therapy development

Research revealed that a single dose of the product can have an effect lasting approximately two weeks, with reduced KIT expression. Credit: Kmpzzz via Shutterstock.

August 16, 2024

ConSynance wins FDA designation for Prader-Willi syndrome therapy – Pharmaceutical Technology

CSTI-500 works by increasing the levels of monoamine neurotransmitters in the synaptic cleft. Image credit: Shutterstock / nobeastsofierce. The US Food and Drug Administration (FDA)

July 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.